Newsroom | 6024 results

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315) heeft vandaag bekendgemaakt dat het een niet-exclusieve licentieovereenkomst heeft gesloten met Qilu Pharmaceutical Co., Ltd. ("Qilu Pharmaceutical") voor een volledig humaan VHH-antilichaammolecuul. Krachtens de overeenkomst verleent Biocytogen aan Qilu Pharmaceutical niet-exclusieve rechten op een volledig humaan VHH-antilichaammolecuul om het bedrijf te ondersteunen in haar onder...

PECHINO--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Pechino) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) oggi ha annunciato la firma di un accordo di licenza non esclusiva con Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) per una molecola di anticorpo VHH interamente umana. Ai sensi dell'accordo, Biocytogen concederà a Qilu Pharmaceutical i diritti non esclusivi a una molecola di anticorpo VHH interamente umana per supportare il suo programma di ricerca e sviluppo di farmaci in...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (« Biocytogen », SSE : 688796 ; HKEX : 02315) a annoncé aujourd’hui la signature d’un accord de licence non exclusif avec Qilu Pharmaceutical Co., Ltd. (« Qilu Pharmaceutical ») portant sur une molécule d’anticorps VHH entièrement humains. Aux termes de cet accord, Biocytogen concède à Qilu Pharmaceutical des droits non exclusifs sur cette molécule d’anticorps VHH afin d'accélérer ses activités de recherche et de développe...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. („Biocytogen“, SSE: 688796; HKEX: 02315) gab heute bekannt, dass es eine nicht-exklusive Lizenzvereinbarung mit Qilu Pharmaceutical Co., Ltd. („Qilu Pharmaceutical“) über ein vollständig humanes VHH-Antikörpermolekül geschlossen hat. Im Rahmen der Vereinbarung gewährt Biocytogen Qilu Pharmaceutical nicht-exklusive Rechte an einem vollständig humanen VHH-Antikörpermolekül, um dessen Forschung und Entwicklung innovativer The...

PEKÍN--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. («Biocytogen», SSE: 688796; HKEX: 02315) anunció hoy la firma de un acuerdo de licencia no exclusiva con Qilu Pharmaceutical Co., Ltd. («Qilu Pharmaceutical») para la utilización de un anticuerpo VHH de origen humano. En virtud del acuerdo, Biocytogen concederá a Qilu Pharmaceutical derechos no exclusivos sobre una molécula de anticuerpo VHH de origen humano para impulsar sus actividades de investigación y desarrollo de trat...

FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $15 million senior credit facility to Bioness Medical, Inc. (“Bioness”), with an initial $10 million funded at closing, and up to $5 million available to support Bioness’s continued growth. Bioness develops and commercializes FDA-approved neurorehabilitation technologies designed to improve mobility and function...

中国北京--(BUSINESS WIRE)--(美国商业资讯)-- 百奥赛图（北京）医药科技股份有限公司（以下简称“百奥赛图”，SSE: 688796；HKEX: 02315）今日宣布，公司近期与齐鲁制药有限公司（以下简称“齐鲁制药”）签署全人纳米抗体分子非排他授权合作协议。根据协议，百奥赛图将向齐鲁制药授权一款全人纳米抗体分子，用于支持其在神经领域创新药物项目中的研发探索。 本次合作涉及的纳米抗体分子由百奥赛图自主研发的RenNano®纳米抗体平台产生。RenNano®平台可用于发现具有良好特异性、亲和力和开发潜力的全人纳米抗体分子，并可为单域抗体、双/多特异性抗体、抗体偶联药物及其他创新形式的设计与开发提供分子基础。通过此次授权，齐鲁制药可结合其自身研发策略，对相关纳米抗体分子开展进一步研究和开发，后续项目的开发形式将根据项目特点和治疗需求灵活推进。 齐鲁制药是中国大型综合性制药企业，长期坚持创新驱动发展，在化学药、生物药及创新药研发方面持续布局，并已建立覆盖早期发现、开发、生产和商业化的体系化能力。此次合作体现了百奥赛图RenNano®平台在神经领域创新药物研发中的应用潜力，也进...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscienc...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscienc...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that new results from the POLARIS clinical program of ETX101, its investigational AAV9-based gene regulation therapy for SCN1A+ Dravet syndrome, will be featured in a platform presentation at the 16th European Epilepsy Congress on September 7, 2026, in Athens, Greece. Professor Ingrid Scheffer, P...